Ovarian cancer (OC) is the second most common gynecologic cancer; however it is responsible for the most gynecologic cancer-related deaths. Apoptosis evasion is an important mechanism in OC tumorigenesis, and the prototypic anti-apoptotic protein, B-cell lymphoma 2 (Bcl-2), is often overexpressed in OC tumors. Gaining a better understanding of the mechanism(s) behind Bcl-2 overexpression and potential extra-anti-apoptotic functions of Bcl-2 could elucidate the importance of elevated Bcl-2 in OC. In the current study, I show through immunohistochemical analysis of normal, benign, and OC tissue sections, that both epithelial and stromal Bcl-2 expression decreases with OC progression. However, the number of Bcl-2-positive lymphocyte nests and the size of these lymphocyte nests increase dramatically with OC progression. Additionally, this study shows that lysophosphatidic acid (LPA), a glycerophospholipid frequently elevated in serum and ascites fluid of OC patients, upregulates Bcl-2 in OC cells. Bcl-2 enzyme-linked immunosorbant assay (ELISA), western blot analysis, reverse transcriptase polymerase chain reaction (RT-PCR), and luciferase reporter assays reveal that LPA increases Bcl-2 promoter, messenger RNA (mRNA), and protein levels in OC cells, but not in normal immortalized ovarian surface epithelial (IOSE) cells. LPA also increases secreted levels of Bcl-2. In vitro human umbilical vein endothelial cell (HUVEC) tube formation assays show that OC-derived Bcl-2 or recombinant human (rh) Bcl-2 promotes aberrant formation of tube-like structures. Though extracellular Bcl-2 does not affect HUVEC cell viability, it may cause aberrant tube formation by inhibiting HUVEC migration. Finally, Bcl-2 ELISA reveals that urinary Bcl-2 levels in OC patients are higher than those in normal individuals and patients with benign gynecologic disease. Urinary Bcl-2 also complements serum CA125 when the two are compared in parallel samples. Furthermore, urinary Bcl-2 decreases following cytoreductive surgery. Altogether, the results suggest that Bcl-2 is important in OC tumorigenesis and angiogenesis. Additionally, urinary Bcl-2 may be a valuable non-invasive biomarker for OC diagnosis and/or screening. Consequently, further elucidation of mechanisms of Bcl-2 overexpression and its extra-apoptotic functions could lead to improved treatment and diagnostic strategies for OC patients.

Methods for determining clusters of data under- specified constraints have recently gained popularity. Although general constraints may be used, we focus on clustering methods with the constraint of a minimal cluster size. In this dissertation, we propose two constrained k-means algorithms: Linear Programming Algorithm (LPA) and Genetic Constrained K-means Algorithm (GCKA). Linear Programming Algorithm modifies the k-means algorithm into a linear programming problem with constraints requiring that each cluster have m or more subjects. In order to achieve an acceptable clustering solution, we run the algorithm with a large number of random sets of initial seeds, and choose the solution with minimal Root Mean Squared Error (RMSE) as our final solution for a given data set. We evaluate LPA with both generic data and simulated data and the results indicate that LPA can obtain a reasonable clustering solution. Genetic Constrained K-Means Algorithm (GCKA) hybridizes the Genetic Algorithm with a constrained k-means algorithm. We define Selection Operator, Mutation Operator and Constrained K-means operator. Using finite Markov chain theory, we prove that the GCKA converges in probability to the global optimum. We test the algorithm with several datasets. The analysis shows that we can achieve a good clustering solution by carefully choosing parameters such as population size, mutation probability and generation. We also propose a Bi-Nelder algorithm to search for an appropriate cluster number with minimal RMSE.

Lysophosphatidic acid (LPA) and transforming growth factor beta (TGFβ) are platelet-derived intercellular mediators of cell proliferation and motility. LPA is a general growth, survival and motility-stimulating factor in mammalian cells. TGFβ prevents proliferation of normal epithelial cells. However, the growth-inhibitory effect of TGFβ is lost or reduced in most malignant cells. Instead, TGFβ promotes migration and invasion of advanced cancer cells. Since LPA and TGFβ are both present in the blood and tumor microenvironments, we were interested in signal integration and functional outcomes in malignant epithelial cells in an LPA and TGFβ co-stimulatory context. In a subset of breast and ovarian cancer cell lines which remain sensitive to the cytostatic effect of TGFβ, we found that LPA up-regulated expression of the cyclin-dependent kinase inhibitor p21Waf1. But this up-regulation was not observed in TGFβ-resistant ones. We examined the possibility that LPA-induced p21 might contribute to the cytostatic response to TGFβ. Indeed, TGFβ alone induced p21 expression weakly in TGFβ-sensitive cells. Serum or serum-borne LPA cooperated with TGFβ to elicit the maximal p21 induction. LPA stimulated p21 via LPA1 and LPA2 receptors and Erk-dependent activation of the CCAAT/enhancer-binding protein beta (C/EBPβ) transcription factor independent of p53. Loss or gain of p21 expression led to a shift between TGFβ sensitive and resistant phenotypes in breast and ovarian cancer cells, indicating that LPA-induced p21 is a key determinant of the growth inhibitory activity of TGFβ. The p21-stimulatory action of LPA is absent from most breast and ovarian cancer cells, leading to their resistance to TGFβ. Therefore we reveal a novel crosstalk between LPA and TGFβ that underlies TGFβ sensitive and resistant phenotypes of breast and ovarian cancer cells. In the next part of our study, we examined the role of interactions between LPA and TGFβ in regulation of tumor cell motility. LPA and, to a much less extent, TGFβ stimulate chemotactic migration and invasion of breast and ovarian cancer cells. However, when combined together with LPA, TGFβ strongly attenuated LPA-driven migration and invasion of breast and ovarian cancer cells. This inhibitory effect was most likely mediated through TGFβ downregulation of expression of LPA1, the major receptor subtype responsible for LPA-regulated cell migration. Knockdown of Smad3 or Smad4 with small hairpin RNA (shRNA) eliminated the inhibitory effects of TGFβ on the LPA1 expression and LPA-dependent cell migration. There are two potential TGFβ inhibitory elements (TIE) (-40 bp and -401 bp) present in the human LPA1 gene promoter. Deletion or point mutation of the distal TIE at around -401 bp abolished the inhibitory effect of TGFβ on the LPA1 promoter activity as revealed by luciferase assays. A DNA pull-down assay showed that the -401-TIE-E2F4/5 sequence was capable of binding Samd3, Smad4, and E2F4/5 in TGFβ-treated cells. The binding of the Smad complex to the native TIE-E2F4/5 sequences of the LPA1 gene promoter was further verified by chromatin immunoprecipitation assay. Our results identify a novel role of TGFβ in the control of LPA1 expression and LPA1-coupled biological activities, adding LPA1 to the list of TGFβ-repressed target genes.

Lysophosphatidic acid (LPA) is a potent bioactive phospholipid mediator that functions through multiple G protein couple receptors (GPCRs). LPA is elevated in ascites of ovarian cancer patients and is involved in growth, survival and metastasis of ovarian cancer cells. Gene promoter analyses revealed that some LPA-target genes share similar sets of binding sites for prominent transcription factors posing the possibility of a general mechanism for activation of their expression by LPA. Detailed investigation of the mechanisms of regulation of cyclooxygenase 2 (Cox-2), a paradigm of LPA-regulated genes, showed that LPA robustly upregulated the expression of Cox-2 in ovarian cancer cells through multiple receptors. LPA induced rapid increase in Cox-2 mRNA and significantly enhanced the stability of Cox-2 transcript with the support of mRNA binding protein HuR. The effects of LPA on Cox-2 transcriptional activation include essential involvement of transcription factor, C/EBP-b. Further studies on mechanisms of activation of C/EBP-b demonstrated that LPA increased phosphorylation, binding and transcriptional activities of C/EBP-b. In addition, activation of C/EBP-b and LPA-target genes required contribution from EGFR. This novel crosstalk between LPA GPCRs and EGFR in mediating transcription factors activation was further explored by investigating the mechanisms of activation of AP-1 and NF-kB by LPA. Activation of AP-1 family of proteins by LPA relied heavily on basal inputs from EGFR as inhibition of EGFR kinase activity with AG1478 caused significant loss of LPA-induced AP-1 expression, binding and transcription activities. Although HGF and other agonists of RTK only weakly stimulate LPA-target genes and transcription factors in ovarian cancer cells, costimulation with HGF in the presence of AG1478 restored LPA signals to both C/EBP-b and AP-1. This suggests an obligatory role for a RTK in LPA-induced transcriptional activation, not necessarily inputs from EGFR. Interestingly, inhibition of EGFR with AG1478 did not interfere with LPA-induced NF-kB activation. Pharmacological inhibition and molecular targeting revealed that only a subset of G proteins participate in the crosstalk between LPA receptors and EGFR. Collectively, these results demonstrate the presence of at least two signals downstream of LPA receptors: one dependent on basal RTK activity and another mediated directly by LPA GPCRs.

During development, oligodendrocytes (OLGs), the myelinating cells of the central nervous system (CNS), undergo a stepwise progression during which OLG progenitors, specified from neural stem/progenitor cells, differentiate into fully mature myelinating OLGs. This progression along the OLG lineage is characterized by well-synchronized changes in morphology and gene expression patterns. The studies presented in this dissertation identified the extracellular factor Autotaxin (ATX) as a novel upstream signal modulating HDAC1/2 activity and gene expression in cells of the OLG lineage. Using the zebrafish as an in vivo model system, as well as rodent primary OLG cultures, this functional property of ATX was found to be mediated by its lysoPLD activity, which has been well-characterized to generate the lipid signaling molecule lysophosphatidic acid (LPA). LPA binds to Gprotein-coupled LPA receptors (LPARs) on the surface of OLGs to initiate downstream signaling events. ATX’s lysoPLD activity was found to modulate HDAC1/2 regulated gene expression during a time window coinciding with the transition from OLG progenitor to early differentiating OLG. When looking further downstream of the ATX-LPA axis, down-regulation of LPA receptor 6 (LPA6) was found to reduce the expression of OLG differentiation genes as well as the overall process network area of OLGs. Thus, LPA6 plays a role in both the gene expression and morphology changes seen in OLG differentiation. These findings prove useful for future therapeutic targets needed for demyelinating diseases of the CNS such as Multiple Sclerosis (MS), in which OLGs fail to differentiate into mature OLGs, needed for remyelination. Additionally, white matter injury has been frequently reported in HIV+ patients. Previous studies showed that HIV-1 Tat (transactivator of transcription), a viral protein that is produced and secreted by HIV-infected cells, is a toxic factor to OLGs. We show here that Tat treatment reduces the expression of OLG differentiation genes and the overall process network area of OLGs. Additionally, Tat-treated OLGs have reduced ATX lysoPLD activity and there is a physical interaction between Tat and ATX. Together, these data strongly suggest functional implications of Tat blocking ATX’s lysoPLD activities and thus the ATX-LPA signaling axis proves to play a significant role in the development of OLGs.

O avanço da terapia intensiva na medicina veterinária vem permitindo a realização de um melhor suporte e monitorização dos animais com sepse grave. Esta é uma síndrome clínica caracterizada por alterações inflamatórias sistêmicas (SIRS) associadas a disfunções orgânicas, como, por exemplo, lesão pulmonar aguda (LPA) e síndrome do desconforto respiratório agudo (SARA). No homem, esta síndrome resulta em uma significante taxa de mortalidade, porém, na medicina veterinária ainda faltam estudos sobre este assunto. Assim, o objetivo deste estudo foi avaliar a ocorrência de complicações respiratórias em animais com sepse grave submetidos à terapia intensiva. Neste estudo foram incluídos 14 animais com sepse grave secundária à piometra. Durante o período de tratamento intensivo os pacientes foram monitorados por meio de: freqüências cardíaca e respiratória, pressão arterial sistólica, débito urinário, pressão venosa central, lactato, saturação venosa central de oxigênio, hemogasometria arterial e radiografias torácicas. Todos os animias (100%) apresentaram alterações respiratórias, destes três cadelas vieram a óbito (21,42%) e 11 (78,57%) receberam alta do tratamento intensivo.Os animais submetidos à terapia intensiva devido ao desenvolvimento de sepse grave secundária à piometra, necessitam de um acompanhamento radiográfico torácico diário, a fim de se estabelecer medidas de suporte respiratório adequadas e, consequentemente, obter menores taxas de mortalidade. / The advances in intensive care has allowed to offer better support to animals with severe sepsis. This is a clinical syndrome characterized by systemic inflammatory response associated with organic dysfunction, such as acute pulmonary injury (ALI) and acute respiratory distress syndrome (ARDS). In humans, this syndrome results in significant mortality, but, in veterinary medicine there are not many studies about this. The aim of this study was to evaluate the development the pulmonary complications in animals submitted to intensive care. In this study were included 14 animals with severe sepsis secondary to pyometra. During the period of intensive care the animals were evaluated: heart and respiratory rates, systolic blood pression, urine output, central venous pression lactate, lactate, central venous saturation, arterial hemogasometric and thoracic x-ray. All animals (100%) had abnormal breathing, three of these dogs eventually died (21.42%) and 11 (78.57%) out of intensive care. Animals with severe sepse secondary to pyometra underwent intensive therapy, requiring a chest radiographic daily in order to establish adequate respiratory support, and thus achieve lower mortality rates.

The role of endogenous molecules in facilitating stem cell differentiation into cardiomyocytes is yet to be fully understood. SPC and S1P, common biolipids, promote cardiac differentiation of mesenchymal stem cells and cardiac progenitor cells, however, the same potential of closely related lysophosphatidic acid (LPA) has only recently become evident. The initial cardio-protection offered by elevated LPA levels in response to acute myocardial infarction and the ability of this biolipid to mediate other cellular fates served as a rationale to investigate the ability of LPA to mediate the cardiac differentiation of the murine P19 teratocarcinoma cell line and further examine the role of signalling molecules critical to lineage commitment. All experiments were carried out using P19 stem cells, cultured in supplemented alpha-minimal essential medium. Cells were aggregated into embryoid bodies in the presence of 5µM LPA in non-tissue grade Petri dishes over the course of 4 days to commence the differentiation process. Inhibitors were added 60 minutes before LPA while control cells were cultured in medium only. Embryoid bodies were transferred to 6-well tissue culture grade plates and cultured for a further 6 days. Cardiac differentiation was assessed by examining the expression of ventricular myosin light chain (MLC1v) by western blot and the role of LPA receptors 1-4, PKC, PI3K, MAPKs, and NF-κB were determined by examining the changes in this expression in the presence of selective inhibitors. The induction and regulation of GATA4, MEF2C, ATF-2, JNK, and YAP was also determined by western blotting. The activity and regulation of transcription factors, AP-1 and NF-κB, and the MAPKs was determined using ELISA kits. LPA induced the differentiation of P19 cells into cardiomyocytes most effectively when used at a concentration of 5µM as evidenced by the expression of MLC1v on day 10 of the differentiation process. Inhibition of LPA receptor 4 (0.1mg/mL Suramin), LPA receptors 1/3 (20µM Ki16425), LPA receptor 2 (7.5nM H2L5186303), PKC (10µM BIM-1), PI3K (20µM LY294002), ERK (20µM PD98059), JNK (10µM SP600125), and NF-κB (0.01nM CAY10470) blocked LPA induced expression of MLC1v. GATA4, MEF2C, pcJun, pJunD, and pATF2 expression increased in a time-dependent manner peaking at day 10 in LPA treated cells. GATA4 and pcJun expression was suppressed by all the inhibitors whereas MEF2C expression was unaffected by CAY10470, pJunD expression was unaffected by H2L5186303, pATF2 and NF-κB expression was unaffected by LY294002, but the latter was enhanced by Suramin. JNK was transiently phosphorylated in all cells whereas YAP was dephosphorylated 24-48 hours after EB formation in LPA treated cells and were both affected by Ki16425 and partially by H2L5186303 treatment. In conclusion, the studies carried out in this thesis have shown that LPA mediates the cardiac differentiation of P19 cells through LPA receptor 2, partially through receptors 1/3, and possibly through receptor 4. Conceivably downstream of these receptors, PKC, PI3K, MAPK, and NF-κB signalling pathways converge on the regulation of cardiac-specific transcription factors GATA4 and MEF2C along with ubiquitous transcription factor AP-1. JNK signalling is initiated through LPA receptors 1/3 and partially through receptor 2 to commence the cardiac program however the role of JNK and YAP in the proliferation of aggregating EBs is yet to be entirely established.

A ribonucleoproteína heterogênea nuclear K (hnRNP K) e o inibidor endógeno da fosfatase 2A (SET) são superexpressos e propostos como marcadores prognósticos em leucemia mieloide aguda e crônica. O objetivo do estudo foi caracterizar a participação das proteínas hnRNP K e SET na leucemogênese da leucemia promielocítica aguda (LPA), assim como na diferenciação celular induzida pelo ácido all-trans retinóico (ATRA). Os resultados iniciais de qRT-PCR demonstram que os níveis de RNAm de HNRNPK e SET estão aumentados em pacientes ao diagnóstico de LPA em comparação com amostras de indivíduos saudáveis e diminuem após indução e durante a manutenção do tratamento. Os resultados foram validados por Western blot, sugerindo hnRNP K e SET como marcadores diagnóstico e de resposta ao tratamento. O knockdown de hnRNP K e SET foi realizado em células de LPA sensível, NB4, e resistente ao ATRA, NB4-R2, utilizando RNA de interferência. Ambas as proteínas também foram testadas como alvo terapêutico com a utilização de inibidores de hnRNP K (U0126) e SET (OP449 e FTY720). A diminuição de hnRNP K nas células levou ao aumento da diferenciação celular granulocítica em ambas as células, principalmente na presença de ATRA, e portanto, foi capaz de reverter o fenótipo de resistência ao ATRA das células NB4-R2. O knockdown de hnRNP K, assim como o tratamento com U0126, levou a perda de viabilidade dessas células por indução de apoptose acompanhada da clivagem da proteína SET. O knockdown de SET em células LPA confirmou que a indução de apoptose em células com knockdown de hnRNP K ocorreu por clivagem e não pela diminuição da proteína SET nas células. Além disso, demonstrou também que SET prejudica a atuação do ATRA no processo de diferenciação celular. O modelo in vivo utilizando transplante de NB4-R2 em camundongos nude confirmou que o trióxido de arsênico (ATO) combinado a U0126 tem um maior potencial contra a progressão tumoral quando comparado ao tratamento isolado com ATO. FTY720 e OP449 tiveram efeito anti-leucêmico significativo com redução da viabilidade celular. Quando em associação, FTY720 e OP449, apresentaram efeito sinérgico significativo em NB4-R2 (CID<0,7). Concluímos que a superexpressão de hnRNP K e SET contribui para o bloqueio da diferenciação celular em promielócitos e prejudicam a atuação do ATRA no tratamento da LPA e, portanto, hnRNPK em associação com a proteína SET representam alvo terapêutico em potencial para terapia anti-leucêmica da LPA, principalmente para pacientes resistentes ao ATRA / Heterogeneous nuclear ribonucleoprotein K (hnRNP K) and endogenous inhibitor of phosphatase 2A (SET) are overexpressed and proposed as prognostic markers in acute and chronic myeloid leukemia. The study aim was to characterize the hnRNP K and SET proteins involvement in acute promyelocytic leukemia leukemia (APL) leukemogenesis as well as all-trans retinoic acid (ATRA) induced cell differentiation. Initial qRT-PCR results demonstrate that HNRNPK and SET mRNA levels are increased in patients diagnosed with APL compare to samples from healthy donors and decrease after induction and during maintenance of treatment. The results were validated by Western blot, suggesting hnRNP K and SET as diagnostic and response to treatment markers. The knockdown of hnRNP K and SET was performed on sensitive, NB4, and ATRA-resistant, NB4-R2, LPA cells using interfering RNA. Both proteins were also tested as a therapeutic target with a use of hnRNP K (U0126) and SET inhibitors (OP449 and FTY720). The decrease of hnRNP K in cells led to increased granulocyte cell differentiation in both cells, especially in the presence of ATRA, and thus was able to reverse the NB4-R2 cells resistance to ATRA phenotype. The hnRNP K knockdown, as well as the treatment with U0126, had a loss of cell viability by induction of apoptosis accompanied by cleavage of the SET protein. The SET knockdown in APL cells confirmed that an induction of apoptosis in cells with hnRNP K knockdown occurred by cleavage and not by the SET protein decrease in the cells. Furthermore, it has also shown that SET impairs the ATRA\'s performance in the cellular differentiation process. The in vivo model using NB4-R2 transplant in nude mice confirmed that arsenic trioxide (ATO) combined with U0126 has a greater potential against tumor progression compared to the treatment isolated with ATO. FTY720 and OP449 have significant anti-leukemic effect reducing cell viability. When in combination, FTY720 and OP449, they had a significant synergistic effect on NB4-R2 (CDI <0.7). We conclude that overexpression of hnRNP K and SET contributes to block cell differentiation in promyelocytes and impair the performance of ATRA in the treatment of APL and therefore hnRNPK in association with a SET protein represent a potential therapeutic target for anti-leukemic therapy of APL, mainly for patients resistant to ATRA

Ovarian cancer is the leading cause of gynecological cancer death in the United States. Even though no single genetic alteration can be attributed to all ovarian cancers, 90% of ovarian tumors express telomerase, a ribonucleoprotein that elongates telomeric (TTAGGG)n repeats de novo. In normal somatic cells, telomerase is absent. In cancer cells, the re-expression of telomerase allows senescence to be bypassed contributing to cellular immortalization, a key step for cellular transformation, making telomerase a potentially important target for therapeutic intervention. Ovarian cancer cells secrete vascular endothelial growth factor (VEGF) and lysophosphatidic acid (LPA) that feedback through their receptors present on ovarian cancer cells to promote cell growth. Since telomerase can be regulated by growth factors, I examined VEGF regulation of telomerase activity and the possible contribution of LPA as an upstream regulator of VEGF-mediated telomerase activity in ovarian cancer. My data reveal that both VEGF and LPA upregulate telomerase activity by ERK 1/2-dependent transcriptional activation within the -976 to the -378 bp hTERT promoter regions where Sp1 is one of the major mediators of VEGF- and LPA-induced transactivation of hTERT. It also identifies telomerase as a novel molecular target of LPA as well as a target of VEGF in non-endothelial cells. In addition I found that, vitamin E, a dietary supplement able to degrade and suppress LPA activity, consistently abrogrates LPA-mediated telomerase activity through transcriptional inhibition of the hTERT -976 to -578 bp promoter regions. Lastly, since epidermal growth factor (EGF) promotes ovarian surface epithelial (OSE) cell growth and EGF receptors are frequently constitutively activated in ovarian cancers, the potential contribution of EGF in the regulation of telomerase activity was also examined. While none of the ovarian cancer cell lines examined produced large amounts of EGF, EGF stimulation of telomerase activity was mediated by Sp1 and c-Myc transcription factors within the hTERT core promoter in an ERK 1/2 /Pyk2-dependent manner. In conclusion, my research shows differential regulation of telomerase activity by growth factor and/or anti-oxidant nutraceuticals. In the future, these factors may be exploited as adjuvant therapy for improved chemotherapeutic benefit to decrease the mortality associated with ovarian cancer.

Increased expression of autotaxin has been shown to promote metastasis formation and cancer proliferation. These actions could be related to the catalytic activity of autotaxin which converts lysophosphatidylcholine into lysophosphatidate extracellularly or non-catalytic functions of autotaxin may be responsible. Also both LPC and LPA have been reported to stimulate migration through their respective receptors. This work investigates the role of autotaxin in controlling the motility of two cancer cell lines. With the use of autotaxin inhibitors we were able to block LPC-induced migration. Knocking-down autotaxin secretion also blocked stimulation of migration by LPC. Autotaxin inhibitors abolished any migratory effects from media collected from autotaxin secreting cells. We determined that LPC alone is unable to stimulate migration. Also we did not observe non-catalytic effects of autotaxin on migration. This thesis provides strong evidence that the inhibition of autotaxin production or activity would provide a beneficial therapy in the prevention of tumour growth or metastasis in patients with autotaxin expressing tumours.